Adagene CEO to Discuss Immune Cell Engagers at H.C. Wainwright Conference
Event summary
- Adagene CEO Peter Luo to participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference on October 15, 2026.
- The event will be held virtually from 1:30 – 2:00 p.m. ET.
- Adagene's lead clinical program, muzastotug (ADG126), has FDA Fast Track designation and is in Phase 1b/2 and Phase 2 clinical studies.
- Muzastotug targets microsatellite stable (MSS) metastatic colorectal cancer (CRC) in combination with anti-PD-1 therapy.
The big picture
Adagene's participation in the H.C. Wainwright conference underscores the growing importance of immune cell engagers in cancer immunotherapy. The company's SAFEbody technology aims to address safety and tolerability challenges, positioning it as a key player in the development of next-generation antibody-based therapies. The strategic focus on MSS metastatic colorectal cancer highlights the unmet needs in this difficult-to-treat patient population.
What we're watching
- Clinical Progress
- How the Phase 1b/2 and Phase 2 clinical studies for muzastotug will progress and whether they will support further development or regulatory approval.
- Regulatory Dynamics
- The pace at which Adagene can navigate the FDA Fast Track designation and secure additional regulatory milestones for its lead program.
- Strategic Partnerships
- Whether Adagene can leverage its SAFEbody technology to forge additional strategic collaborations beyond its existing partnerships.
Related topics
